title: Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
abstract: We investigated economic costs from patients with Parkinson's disease (PD) in Shanghai, China, which could be used as a baseline for future evaluations. Data were collected from 190 patients by interview during 1-year period. Direct medical care costs averaged approximately Chinese yuan, renminbi (RMB) 4,305 (USD 519, or EUR 410) per year per patient, of which drugs (RMB 2,677) accounted for the major costly component. Nonmedical direct costs were much less than direct health care costs, averaging approximately RMB 3,301 (USD 398, or EUR 314). Costs due to loss of productivity averaged approximately RMB 73 (USD 8.8, or EUR 7.0) per patient per year. Taken together, the overall mean annual cost for PD in our series was approximately RMB 7,679 (USD 925, or EUR 731), and these costs accounted for around half of the mean annual income. Total cost was significantly associated with the disease severity and the frequency of outpatient visits. In addition, levodopa equivalent dose (LED) and the number of drugs being taken were also closely related with the drug cost. The results indicate that the economic burden of Chinese PD patients is heavy.
authors.affiliation: Department of Neurology & Institute of Neurology, Ruijin Hospital affiliated to the Medical School of Shanghai Jiaotong University, Shanghai, China.
authors.forename: Gang
authors.initials: G
authors.lastname: Wang
authors.forename: Qi
authors.initials: Q
authors.lastname: Cheng
authors.forename: Rui
authors.initials: R
authors.lastname: Zheng
authors.forename: Yu-Yan
authors.initials: YY
authors.lastname: Tan
authors.forename: Xiao-Kang
authors.initials: XK
authors.lastname: Sun
authors.forename: Hai-Yan
authors.initials: HY
authors.lastname: Zhou
authors.forename: Xiao-Lai
authors.initials: XL
authors.lastname: Ye
authors.forename: Ying
authors.initials: Y
authors.lastname: Wang
authors.forename: Zeng
authors.initials: Z
authors.lastname: Wang
authors.forename: Bo-Min
authors.initials: BM
authors.lastname: Sun
authors.forename: Sheng-Di
authors.initials: SD
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care / Q000191:economics; D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use; D002681:China; D003131:Combined Modality Therapy / Q000191:economics; D017281:Cost of Illness; D003365:Costs and Cost Analysis / Q000706:statistics & numerical data; D003695:Delivery of Health Care / Q000191:economics; D003906:Developing Countries; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006801:Humans; D007980:Levodopa / Q000191:economics / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000191:economics*; D010343:Patient Admission / Q000191:economics; D010348:Patient Care Team / Q000191:economics; D011157:Population Dynamics; D012189:Retrospective Studies
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa